|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
US7112661B1
(en)
|
1998-10-30 |
2006-09-26 |
The Research Foundation Of State University Of New York |
Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2369292C
(en)
|
1999-04-09 |
2010-09-21 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of modulating the activity of functional immune molecules
|
|
WO2001029246A1
(fr)
|
1999-10-19 |
2001-04-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production d'un polypeptide
|
|
AU2001294175A1
(en)
|
2000-10-06 |
2002-04-22 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of purifying antibody
|
|
EA013563B1
(ru)
|
2000-10-06 |
2010-06-30 |
Киова Хакко Кирин Ко., Лтд. |
Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
|
|
IT1320715B1
(it)
|
2000-10-19 |
2003-12-10 |
Cselt Centro Studi Lab Telecom |
Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
WO2004006955A1
(en)
|
2001-07-12 |
2004-01-22 |
Jefferson Foote |
Super humanized antibodies
|
|
US7497862B2
(en)
|
2001-08-03 |
2009-03-03 |
Tyco Healthcare Group Lp |
Tissue marking apparatus and method
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
|
AR053489A1
(es)
|
2005-05-24 |
2007-05-09 |
Morphosys Ag |
Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
|
|
JP5362359B2
(ja)
|
2005-10-12 |
2013-12-11 |
モルフォシス アーゲー |
ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
|
|
EP2975057A1
(en)
|
2006-07-10 |
2016-01-20 |
Fujita Health University |
Novel anti-cd73 antibody
|
|
HRP20191115T1
(hr)
|
2006-09-26 |
2019-09-20 |
Genmab A/S |
Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
|
BRPI0822049B1
(pt)
|
2007-12-17 |
2021-11-16 |
Pfizer Limited |
Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
|
|
NZ589880A
(en)
|
2008-06-16 |
2012-10-26 |
Immunogen Inc |
Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate
|
|
KR20110043786A
(ko)
|
2008-08-20 |
2011-04-27 |
센토코 오르토 바이오테크 인코포레이티드 |
조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도
|
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
LT2621531T
(lt)
|
2010-09-27 |
2017-04-10 |
Morphosys Ag |
Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
GB2486424A
(en)
|
2010-12-13 |
2012-06-20 |
Univ Sussex |
Markers for plasma cell disorders
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
CN103502472B
(zh)
*
|
2011-02-28 |
2017-06-06 |
弗·哈夫曼-拉罗切有限公司 |
生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
|
|
JP6024025B2
(ja)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
少容量投与用のアロタイプ選択抗体の限外濾過濃縮
|
|
GB201203938D0
(en)
|
2012-03-06 |
2012-04-18 |
Binding Site Group The Ltd |
Assay system
|
|
GB201212900D0
(en)
|
2012-07-20 |
2012-09-05 |
Binding Site Group The Ltd |
Triage scoring system
|
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20160075766A1
(en)
|
2013-05-21 |
2016-03-17 |
Roche Diagnostics Operations, Inc. |
Method for producing antibodies using ovine b-cells and uses thereof
|
|
EP3009518B1
(en)
*
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
|
SG10201800592SA
(en)
|
2013-07-30 |
2018-03-28 |
Sbi Biotech Co Ltd |
Medicament comprising anti-phospholipase d4 antibody
|
|
EP3063173B1
(en)
|
2013-10-31 |
2020-07-29 |
Sanofi |
Specific anti-cd38 antibodies for treating human cancers
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US10617757B2
(en)
|
2014-08-08 |
2020-04-14 |
The Regents Of The University Of California |
Methods for treating multiple myeloma
|
|
MY192918A
(en)
|
2014-09-09 |
2022-09-15 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
MA41555A
(fr)
|
2015-02-17 |
2017-12-26 |
Millennium Pharm Inc |
Polythérapie pour le traitement du cancer
|
|
HRP20210552T1
(hr)
|
2015-05-13 |
2021-05-14 |
Morphosys Ag |
Liječenje multiplog mijeloma (mm)
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
PL3827845T3
(pl)
|
2015-11-03 |
2022-07-11 |
Janssen Biotech, Inc. |
Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
|
|
US20170121417A1
(en)
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
|
BR112019000544A2
(pt)
*
|
2016-07-15 |
2019-04-24 |
Takeda Pharmaceutical Company Limited |
métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
|
|
US20180117150A1
(en)
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
|
US11392902B2
(en)
|
2017-06-06 |
2022-07-19 |
United Parcel Service Of America, Inc. |
Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
|
|
CA3079242A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
AU2019208102B2
(en)
|
2018-01-12 |
2025-10-09 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-CD38 antibodies
|
|
CN120501855A
(zh)
|
2019-05-14 |
2025-08-19 |
赛诺菲-安万特美国有限责任公司 |
给予抗cd38抗体以治疗多发性骨髓瘤的方法
|